Genotype in diabetes treatment and prevention
A technology of diseases and haplotypes, applied in metabolic diseases, disease diagnosis, allergic diseases, etc., can solve problems such as metabolic abnormalities
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0070] Example 1: Phase II of TrialNet
[0071] Three arms (A: 3 sc x 20 μg GAD-alum (n=48); B: 2 x 20 μg GAD-alum and 1 Alum (n=49); and C: 3x Alum (n=48)) randomized study, Wherrett DK et al., (Lancet, 2011 Jul 23; 378(9788):319-27) reported, at year 1, according to The 2-h AUC of C-peptide adjusted for age, sex and baseline C-peptide value was 0.412 nmol / L (0.349-0.478) in A in the GAD-alum group and 0.382 in the GAD-alum plus alum group in B nmol / L (0.322-0.446), and C was 0.413 nmol / L (0.351-0.477) in the alum group, corresponding to the mean C-peptide relative The mean losses from baseline were 44%, 42% and 41%. The authors noted that baseline and one-year C-peptide levels mirrored findings in the control groups of the other three TrialNet studies treated within 3 months of diagnosis, which also showed that alum alone was responsible for the loss of insulin secretion at 12 months No effect.
[0072] The adjusted trailing 12-month declines are thus 3.7%, 3.5% and 3.42...
Embodiment 2
[0079] Example 2: DiaPrevIt
[0080] A randomized, double-blind, placebo-controlled study (DiaPREV-IT, ClinicalTrials.gov Identifier: NCT01122446) of 50 healthy children with multiple islet autoantibodies who did not already have diabetes found that preventive treatment with GAD-alum Does not affect progression of clinical T1D onset.
[0081] The study was conducted in children aged 4-17.9 years (median age 5.2) with GADA and at least one additional islet autoantibody. Recruitment was completed in 2012 and the follow-up period was 5 years. from Eligible children of the (DiPiS) Diabetes Prediction, Environmental Determinants of Diabetes in the Young (TEDDY) study received two subcutaneous injections of 20 ug GAD-alum (n=25) or placebo (n=25) 30 days apart. The exclusion criteria were HLA DQB1*06:02 positive.
[0082] Islet cell autoantibodies predict the clinical onset of T1D, and children with more than one islet autoantibody have a 70% risk of developing T1D within 10 ye...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 



